HK1164859A1 - Inhibitors of brutons tyrosine kinase - Google Patents

Inhibitors of brutons tyrosine kinase

Info

Publication number
HK1164859A1
HK1164859A1 HK12105531.1A HK12105531A HK1164859A1 HK 1164859 A1 HK1164859 A1 HK 1164859A1 HK 12105531 A HK12105531 A HK 12105531A HK 1164859 A1 HK1164859 A1 HK 1164859A1
Authority
HK
Hong Kong
Prior art keywords
inhibitors
tyrosine kinase
brutons tyrosine
brutons
kinase
Prior art date
Application number
HK12105531.1A
Other languages
English (en)
Chinese (zh)
Inventor
史蒂文．約瑟夫．貝特爾
費利伯茲．菲羅厄茲尼亞
丹尼爾．菲什洛克
洪俊裴
婁岩
馬修．
．盧卡斯
蒂莫西．
．歐文斯
凱沙布．薩爾馬
扎卡裡．凱文．斯威尼
喬舒亞．保羅．蓋爾蓋伊．塔伊格爾利
Original Assignee
霍夫曼-拉羅奇有限公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42097405&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1164859(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 霍夫曼-拉羅奇有限公司 filed Critical 霍夫曼-拉羅奇有限公司
Publication of HK1164859A1 publication Critical patent/HK1164859A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/24—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/32—Phthalazines with oxygen atoms directly attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
HK12105531.1A 2009-03-02 2012-06-07 Inhibitors of brutons tyrosine kinase HK1164859A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20902109P 2009-03-02 2009-03-02
US30006410P 2010-02-01 2010-02-01
PCT/EP2010/052394 WO2010100070A1 (en) 2009-03-02 2010-02-25 Inhibitors of bruton's tyrosine kinase

Publications (1)

Publication Number Publication Date
HK1164859A1 true HK1164859A1 (en) 2012-09-28

Family

ID=42097405

Family Applications (2)

Application Number Title Priority Date Filing Date
HK12105531.1A HK1164859A1 (en) 2009-03-02 2012-06-07 Inhibitors of brutons tyrosine kinase
HK16104764.8A HK1216887A1 (zh) 2009-03-02 2016-04-26 布魯頓酪氨酸激酶的抑制劑

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK16104764.8A HK1216887A1 (zh) 2009-03-02 2016-04-26 布魯頓酪氨酸激酶的抑制劑

Country Status (20)

Country Link
US (1) US8299077B2 (pt)
EP (1) EP2403846B1 (pt)
JP (1) JP5512707B2 (pt)
KR (1) KR101347978B1 (pt)
CN (2) CN105001206A (pt)
AR (1) AR076066A1 (pt)
AU (1) AU2010220435B2 (pt)
BR (1) BRPI1009112A2 (pt)
CA (1) CA2753341C (pt)
CL (1) CL2011002115A1 (pt)
ES (1) ES2607644T3 (pt)
HK (2) HK1164859A1 (pt)
IL (1) IL214351A0 (pt)
MX (1) MX339583B (pt)
PE (2) PE20151336A1 (pt)
RU (1) RU2542585C2 (pt)
SG (1) SG173816A1 (pt)
TW (2) TWI519529B (pt)
WO (1) WO2010100070A1 (pt)
ZA (1) ZA201301679B (pt)

Families Citing this family (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators
MX2010013478A (es) * 2008-07-02 2010-12-20 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de cinasa.
CA2730930C (en) 2008-07-16 2015-01-13 Pharmacyclics, Inc. Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors
EP2708538B1 (en) 2009-03-23 2015-08-12 Glenmark Pharmaceuticals S.A. Process for preparing fused pyrimidine-dione derivatives, useful as as TRPA1 modulators
CA3154024C (en) 2010-06-03 2024-02-27 Pharmacyclics Llc Use of inhibitors of bruton's tyrosine kinase (btk) in the treatment of relapsed or refractory follicular lymphoma
AR082590A1 (es) * 2010-08-12 2012-12-19 Hoffmann La Roche Inhibidores de la tirosina-quinasa de bruton
KR20180031823A (ko) 2010-09-01 2018-03-28 질레드 코네티컷 인코포레이티드 피리다지논, 그의 제조 방법 및 사용 방법
CN106220614B (zh) 2010-09-01 2019-07-16 吉利德康涅狄格有限公司 吡啶酮/吡嗪酮、其制备方法及使用方法
JP5859640B2 (ja) 2011-05-17 2016-02-10 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ ブルトンチロシンキナーゼ阻害剤
AU2012275275A1 (en) * 2011-06-28 2014-01-23 Pharmacyclics Llc Methods and compositions for inhibition of bone resorption
EA201490265A1 (ru) 2011-07-13 2014-12-30 Фармасайкликс, Инк. Ингибиторы тирозинкиназы брутона
CA2841801A1 (en) 2011-08-17 2013-02-21 F.Hoffmann-La Roche Ag Inhibitors of bruton's tyrosine kinase
EA201892766A1 (ru) * 2011-10-19 2019-08-30 Фармасайкликс Элэлси ПРИМЕНЕНИЕ ИНГИБИТОРОВ ТИРОЗИНКИНАЗЫ БРУТОНА (Btk)
UA111756C2 (uk) 2011-11-03 2016-06-10 Ф. Хоффманн-Ля Рош Аг Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона
BR112014010460A2 (pt) * 2011-11-03 2017-04-18 Hoffmann La Roche composto, composição farmacêutica, processo para produzir uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica
AR088642A1 (es) * 2011-11-03 2014-06-25 Genentech Inc Compuestos de piperazina alquilados
BR112014013582A2 (pt) * 2011-12-09 2017-06-13 Hoffmann La Roche inibidores de quinase de tirosina de bruton
WO2013157021A1 (en) 2012-04-20 2013-10-24 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
EP2838898B1 (en) 2012-04-20 2017-01-18 Advinus Therapeutics Limited Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MX2015001081A (es) 2012-07-24 2015-10-14 Pharmacyclics Inc Mutaciones asociadas a resistencia a inhibidores de la tirosina cinasa de bruton (btk).
CA2881519A1 (en) 2012-08-10 2014-02-13 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as bruton's tyrosine kinase (btk) inhibitors
CA2881761A1 (en) 2012-09-13 2014-03-20 Christine E. Brotherton-Pleiss Inhibitors of bruton's tyrosine kinase
MX2015006162A (es) * 2012-11-16 2015-08-14 Hoffmann La Roche Inhibidores de la tirosina-cinasa de bruton.
BR112015010121A2 (pt) * 2012-11-30 2017-07-11 Hoffmann La Roche inibidores de quinase de tirosina de bruton
US9663494B2 (en) 2013-03-05 2017-05-30 Hoffmann-La Roche Inc. Inhibitors of bruton's tyrosine kinase
CN105051028B (zh) * 2013-03-05 2017-06-09 豪夫迈·罗氏有限公司 布鲁顿氏酪氨酸激酶抑制剂
US11491154B2 (en) 2013-04-08 2022-11-08 Dennis M. Brown Therapeutic benefit of suboptimally administered chemical compounds
CN104884458B (zh) 2013-04-25 2017-04-12 百济神州有限公司 作为蛋白质激酶抑制剂的稠合杂环化合物
CN104177338B (zh) * 2013-05-22 2018-04-03 南京勇山生物科技有限公司 一类布鲁顿激酶抑制剂
CN104211703B (zh) * 2013-05-30 2018-04-03 南京勇山生物科技有限公司 一类作为布鲁顿激酶抑制剂的稠杂环化合物
BR112015029972A2 (pt) 2013-07-03 2017-07-25 Hoffmann La Roche composto, composição farmacêutica, processo para a preparação de uma composição farmacêutica, método para o tratamento de uma doença, conjunto e utilização de um composto
KR20160104612A (ko) 2013-07-26 2016-09-05 업데이트 파마 인코포레이트 비산트렌의 치료 효과 개선용 조성물
KR101742550B1 (ko) 2013-07-26 2017-06-01 카나 바이오사이언스, 인코포레이션 신규 트리아진 유도체
CA2920534A1 (en) 2013-08-12 2015-02-19 Pharmacyclics Llc Methods for the treatment of her2 amplified cancer
CN112552401B (zh) 2013-09-13 2023-08-25 广州百济神州生物制药有限公司 抗pd1抗体及其作为治疗剂与诊断剂的用途
US9512084B2 (en) * 2013-11-29 2016-12-06 Novartis Ag Amino pyrimidine derivatives
MX2016007171A (es) 2013-12-05 2016-09-08 Hoffmann La Roche Compuestos de heteroaril piridona y azapiridona con funcionalidad electrofila.
RU2653500C2 (ru) * 2013-12-13 2018-05-10 Ф. Хоффманн-Ля Рош Аг Ингибиторы тирозинкиназы брутона
CA2942528A1 (en) 2014-03-20 2015-09-24 Pharmacyclics Inc. Phospholipase c gamma 2 and resistance associated mutations
US10544225B2 (en) 2014-07-03 2020-01-28 Beigene, Ltd. Anti-PD-L1 antibodies and their use as therapeutics and diagnostics
EP3201186B1 (en) * 2014-10-02 2019-02-27 F. Hoffmann-La Roche AG Pyrazole carboxamide compounds for use in the treament of disorders mediated by bruton's tyrosine kinase (btk)
CN104402828A (zh) * 2014-11-05 2015-03-11 定陶县友帮化工有限公司 一种3-氨基-4-溴-6-氯哒嗪的合成方法
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
EP3042903B1 (en) 2015-01-06 2019-08-14 Impetis Biosciences Ltd. Substituted hetero-bicyclic compounds, compositions and medicinal applications thereof
MA50817B1 (fr) 2015-07-02 2021-10-29 Acerta Pharma Bv Formes et formulations solides de (s)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-n-(pyridin-2-yl)benzamide
RU2608128C1 (ru) * 2015-11-12 2017-01-13 федеральное государственное бюджетное образовательное учреждение высшего образования "Ростовский государственный медицинский университет" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РостГМУ Минздрава России) Способ лечения больных с х-сцепленной агаммаглобулинемией
WO2017123695A1 (en) * 2016-01-13 2017-07-20 Boehringer Ingelheim International Gmbh Isoquinolones as btk inhibitors
KR102489537B1 (ko) * 2016-06-22 2023-01-17 상하이 포천 파마슈티컬 씨오 엘티디 단백질 키나제 억제제로서의 치환된 피롤로[2,3-d]피리다진-4-온 및 피라졸로[3,4-d]피리다진-4-온
WO2018007885A1 (en) 2016-07-05 2018-01-11 Beigene, Ltd. COMBINATION OF A PD-l ANTAGONIST AND A RAF INHIBITOR FOR TREATING CANCER
CN110049976A (zh) 2016-07-21 2019-07-23 比奥根Ma公司 布鲁顿氏酪氨酸激酶抑制剂的琥珀酸盐形式和组合物
CN116478166A (zh) 2016-08-16 2023-07-25 百济神州(苏州)生物科技有限公司 一种化合物的晶型、其制备和用途
WO2018033135A1 (en) 2016-08-19 2018-02-22 Beigene, Ltd. Use of a combination comprising a btk inhibitor for treating cancers
US20190201409A1 (en) 2016-09-19 2019-07-04 Mei Pharma, Inc. Combination therapy
JP6890179B2 (ja) 2016-12-02 2021-06-18 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式アミド化合物及びその使用方法
CA3045339A1 (en) 2016-12-03 2018-06-07 Juno Therapeutics, Inc. Methods and compositions for use of therapeutic t cells in combination with kinase inhibitors
EP3573989A4 (en) 2017-01-25 2020-11-18 Beigene, Ltd. CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) -PIPERIDINE-4-YL) -2- (4-PHENOXYPHENYL) -4,5,6,7-TETRAHYDROPYRAZOLO [1,5-A ] PYRIMIDINE-3-CARBOXAMIDE, MANUFACTURING AND USES THEREOF
AU2018290532A1 (en) 2017-06-26 2019-11-21 Beigene, Ltd. Immunotherapy for hepatocellular carcinoma
US11098058B2 (en) 2017-07-14 2021-08-24 Genentech, Inc. Bicyclic ketone compounds and methods of use thereof
CN110997677A (zh) 2017-08-12 2020-04-10 百济神州有限公司 具有改进的双重选择性的Btk抑制剂
KR102613433B1 (ko) 2017-10-11 2023-12-13 주식회사 대웅제약 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물
JP2021501183A (ja) 2017-10-31 2021-01-14 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 二環式のスルホン及びスルホキシド、並びにその使用方法
US11786529B2 (en) 2017-11-29 2023-10-17 Beigene Switzerland Gmbh Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors
CA3085366A1 (en) 2017-12-22 2019-06-27 Petra Pharma Corporation Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
CN111961035B (zh) * 2019-05-20 2022-11-01 南京科技职业学院 一类含有羟基异喹啉类结构的化合物、药物组合物以及其应用
WO2023152888A1 (ja) * 2022-02-10 2023-08-17 カルナバイオサイエンス株式会社 フルオロイソキノリン化合物およびその製造法
US11786531B1 (en) 2022-06-08 2023-10-17 Beigene Switzerland Gmbh Methods of treating B-cell proliferative disorder

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7312341B2 (en) 2002-09-09 2007-12-25 Cgi Pharmaceuticals, Inc. 6-aryl-imidazo[1,2-a] pyrazin-8-ylamines, method of making, and method of use thereof
US7405295B2 (en) 2003-06-04 2008-07-29 Cgi Pharmaceuticals, Inc. Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds
UY29301A1 (es) * 2004-12-24 2006-07-31 Astrazeneca Ab Derivados amida
PE20080839A1 (es) * 2006-09-11 2008-08-23 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
PE20081370A1 (es) * 2006-09-11 2008-11-28 Cgi Pharmaceuticals Inc Determinadas amidas sustituidas, metodo de elaboracion y metodo de uso de las mismas
ES2499017T3 (es) 2007-10-23 2014-09-26 F. Hoffmann-La Roche Ag Nuevos inhibidores de quinasa
WO2009077334A1 (en) 2007-12-14 2009-06-25 F. Hoffmann-La Roche Ag Novel imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives
MX2010008197A (es) 2008-02-05 2010-08-23 Hoffmann La Roche Nuevas piridinonas y piridazinonas.
US7683064B2 (en) 2008-02-05 2010-03-23 Roche Palo Alto Llc Inhibitors of Bruton's tyrosine kinase
PE20100851A1 (es) 2008-06-24 2011-01-31 Hoffmann La Roche PIRIDIN-2-ONAS Y PIRIDAZIN-3-ONAS SUSTITUIDAS COMO INHIBIDORES DE Btk
MX2010013478A (es) 2008-07-02 2010-12-20 Hoffmann La Roche Nuevas fenilpirazinonas como inhibidores de cinasa.

Also Published As

Publication number Publication date
AU2010220435B2 (en) 2015-12-24
IL214351A0 (en) 2011-09-27
TW201439080A (zh) 2014-10-16
MX339583B (es) 2016-06-01
CA2753341C (en) 2017-02-21
KR101347978B1 (ko) 2014-01-14
EP2403846A1 (en) 2012-01-11
KR20110111325A (ko) 2011-10-10
PE20151336A1 (es) 2015-09-18
SG173816A1 (en) 2011-09-29
JP5512707B2 (ja) 2014-06-04
RU2542585C2 (ru) 2015-02-20
US20100222325A1 (en) 2010-09-02
CA2753341A1 (en) 2010-09-10
CN102341383A (zh) 2012-02-01
AR076066A1 (es) 2011-05-18
JP2012519200A (ja) 2012-08-23
US8299077B2 (en) 2012-10-30
MX2011008643A (es) 2011-09-06
BRPI1009112A2 (pt) 2016-03-01
WO2010100070A1 (en) 2010-09-10
CN105001206A (zh) 2015-10-28
HK1216887A1 (zh) 2016-12-09
CN102341383B (zh) 2015-09-16
TWI519529B (zh) 2016-02-01
EP2403846B1 (en) 2016-11-02
CL2011002115A1 (es) 2012-03-30
ZA201301679B (en) 2015-06-24
ES2607644T3 (es) 2017-04-03
RU2011140064A (ru) 2013-04-10
AU2010220435A1 (en) 2011-08-18
TW201035072A (en) 2010-10-01
PE20120081A1 (es) 2012-02-06

Similar Documents

Publication Publication Date Title
HK1216887A1 (zh) 布魯頓酪氨酸激酶的抑制劑
IL280173A (en) Broton tyrosine kinase inhibitors
HK1186186A1 (en) Inhibitors of brutons tyrosine kinase
HK1259148A1 (zh) 用作atr激酶抑制劑的化合物
HK1194381A1 (en) Inhibitors of brutons tyrosine kinase
HK1197060A1 (en) Inhibitors of brutons tyrosine kinase
HK1212689A1 (zh) 布魯頓氏酪氨酸激酶抑制劑
EP2632898A4 (en) HETEROCYCLIC TYROSINE KINASE HEMMER
HK1167655A1 (zh) -末端激酶抑制劑
HK1211293A1 (en) Brutons tyrosine kinase inhibitors
HK1179477A1 (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
EP2515657A4 (en) TYROSINE KINASE INHIBITORS
IL220212A0 (en) Aminopyrimidine kinase inhibitors
ZA201204136B (en) Pteridinones as inhibitors of polo-like kinase
HK1161260A1 (zh) 用作 激酶抑制劑的化合物
ZA201108048B (en) P38map kinase inhibitor
HK1200816A1 (en) Inhibitors of brutons tyrosine kinase
EP2558099A4 (en) Kinase Inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
HK1210461A1 (en) Inhibitors of brutons tyrosine kinase
HK1210779A1 (en) Inhibitors of brutons tyrosine kinase
IL220187A0 (en) Inhibitors of sphingosine kinase
EP2382210A4 (en) INHIBITORS OF PYRIMIDINEDIAMINE KINASE
EP2231152A4 (en) THIENOPYRANONES AS KINASE INHIBITORS

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20190225